Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02757755 · ClinicalTrials.gov registry record · Phase 1

Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults

A Phase 1 study of Healthy Volunteers, sponsored by Armata Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
12
Enrollment target
1
Study location

NCT02757755: Completed Phase 1 study of Healthy Volunteers, sponsored by Armata Pharmaceuticals.

NCT02757755 is a Phase 1 study of Healthy Volunteers that has completed, run by Armata Pharmaceuticals. The registered enrollment target is 12 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02757755, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Armata Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

This study will examine the safety of ascending doses of AB-SA01 when topically applied to intact skin of healthy adults.

Primary Outcome

Occurrence, intensity, and relationship of adverse events (AEs) from first dose through the End of Study visit

Conditions Studied

Interventions

  • BIOLOGICAL AB-SA01 (10^8 PFU per phage)
  • BIOLOGICAL AB-SA01 (10^9 PFU per phage)
  • BIOLOGICAL Placebo (for Cohort 10^8)
  • BIOLOGICAL Placebo (for Cohort 10^9)

Study Locations (1)

Maryland

  • Clinical Trials Center, WRAIR - Silver Spring

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2016-05
Est. Completion 2016-08
Phase Phase 1
Armata Pharmaceuticals

11 total trials

What the finished NCT02757755 record still lists

NCT02757755 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 4 interventions - of which AB-SA01 (10^8 PFU per phage) is the first listed.

NCT02757755 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT02757755 about?

NCT02757755 is a clinical study titled "Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults". This study will examine the safety of ascending doses of AB-SA01 when topically applied to intact skin of healthy adults.

What is the current status of trial NCT02757755?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2016-05. Estimated completion is 2016-08.

What conditions does trial NCT02757755 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT02757755?

The interventions under investigation include: AB-SA01 (10^8 PFU per phage) (BIOLOGICAL), AB-SA01 (10^9 PFU per phage) (BIOLOGICAL), Placebo (for Cohort 10^8) (BIOLOGICAL), Placebo (for Cohort 10^9) (BIOLOGICAL).

Who is sponsoring clinical trial NCT02757755?

This trial is sponsored by Armata Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02757755 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02757755's enrollment target sits among peer trials

12 252nd of 283 higher than 26 of 283 other Healthy Volunteers trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Volunteers trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02757755, the US trial registry maintained by the National Library of Medicine. NCT02757755 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.